Clinical trials: Infliximab
Crohn's Disease
Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)
This is a double-blind, double-dummy, prednisolone-controlled, multi-center, randomized, parallel-group clinical study to evaluate the therapeutic efficacy of repeated infliximab infusions in order to maintain Crohn's disease…
- Trial name
- NCT00796250
- Testing
- Infliximab, AZA, Prednisolone
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)
The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis (RA) subjects achieving a "good" or "moderate" DAS28 response (EULAR28 criteria) at Week 16 with etanercept 50 mg subcutaneously (SC) once weekly in…
- Trial name
- NCT00099554
- Testing
- Etanercept
- Volunteers
- 200 people
- Sponsor
- Amgen
Healthy
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects
The purpose of this study is to compare the pharmacokinetics, safety, tolerability and immunogenicity of SB2 and Remicade (EU sourced Remicade and US sourced Remicade) in healthy subjects.
- Trial name
- NCT01922336
- Testing
- SB2, EU Remicade, US Remicade
- Where
- Germany
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Crohn's Disease
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.
- Trial name
- NCT02096861
- Testing
- CT-P13, Remicade
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Celltrion
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Arthritis, Rheumatoid
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid arthritis (RA) participants who have an inadequate response to their current treatment with either etanercept + methotrexate or adalimumab +…
- Conditions
- Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
- Trial name
- NCT01004432
- Testing
- Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX)
- Where
- 117 sites in United States, Austria and 6 more
- Volunteers
- 433 people
- Sponsor
- Janssen Biotech, Inc.
Crohn's Disease
Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohn's disease in Greek patients who have previously responded to…
- Trial name
- NCT00307931
- Testing
- Certolizumab pegol
- Where
- 5 sites in Greece
- Volunteers
- 16 people
- Sponsor
- UCB Pharma
Psoriasis
Assessment of Long-Term Infliximab for Psoriasis (P05319)
This is a prospective Phase 4, open-label, non-randomized, observational, multi-center study of infliximab in participants with plaque-type psoriasis to assess the clinical response in real-world practice of long-term maintenance…
- Trial name
- REALITY (NCT00779675)
- Testing
- Infliximab
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
- Trial name
- NCT00725296
- Testing
- Remicade (Infliximab)
- Volunteers
- 178 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease
A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease
A study of infliximab in patients with Fistulizing Crohn's Disease
- Trial name
- NCT00207766
- Volunteers
- 306 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with…
- Trial name
- FALLA (NCT01083160)
- Where
- 12 sites in Mexico
- Volunteers
- 82 people
- Sponsor
- Abbott
Crohn Disease
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the…
- Trial name
- NCT04312659
- Testing
- Infliximab
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Healthy
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)
In this study, healthy volunteers will receive a single intravenous dose of either PF-06438179 or infliximab (United States) or infliximab (European Union).
- Trial name
- NCT01844804
- Testing
- PF-06438179, Remicade
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection
This study compares the similarity of the proportion of subjects who achieved ACR20 at week 30 in the two groups.
- Trial name
- NCT04178850
- Testing
- GB242, Infliximab
- Where
- China
- Volunteers
- 568 people
- Sponsor
- Genor Biopharma Co., Ltd.
Rheumatoid Arthritis
Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-weekly to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab or adalimumab plus methotrexate.
- Trial name
- SERUM (NCT01783015)
- Testing
- Etanercept
- Where
- 15 sites in Australia, Belgium and 5 more
- Volunteers
- 16 people
- Sponsor
- Pfizer